Our current study of CD133 expression following exposure of glioma cells to rapamycin differs from those previously conducted using colorectal and gastric cancer cells due to the different cellular context in glioma from the others, because CD133 expression in the C6-CD133 cell line was reproducibly and significantly downregulated by rapamycin. The gene discussed is PROM1; the disease is glioma.